Agonist hold Antagonist Protocol versus Antagonist Protocol in Intracytoplasmic Sperm Injection for Infertile Patients with Polycystic Ovary Syndrome

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is currently thought to emerge from a complex interaction of genetic and environmental traits.Polycystic Ovary Syndrome is the most common endocrinopathy among reproductive-aged women Objectives: The aim of this study was to compare between agonist hold antagonist protocol and antagonist protocol in ICSI for Infertile patients with PCOs as regard the number of oocytes retrieved, fertilization rate, implantation rate and clinical pregnancy rate. Patients and methods: This was a prospective comparative study, which was conducted at Assisted Reproduction Unit at Qena University Hospital.This work had been conducted on infertile women with PCOS undergoing ICSI in ART unit in obstetrics and gynecology department, Qena University hospital from January 2019 to June 2020. Results:The number of implanted embryos was significantly higher in agonist hold antagonist protocol group compared to antagonist protocol group (p<0.001).Also, clinical pregnancy was found to be significantly higher in agonist hold antagonist protocol group compared to antagonist protocol group (p=0.009). On the other hand, prevalence of OHSS was significantly higher in antagonist protocol group compared to agonist hold antagonist protocol group (p=0.023).There was no statistically significant difference between the two groups regarding β-HCG (p>0.05). Conclusion: GnRH agonis thold antagonist may be a preferred protocol for PCOS patients treated with ICSI in view of the reduction of the risk of OHSS, the shorter stimulation time and better pregnancy outcome.